Gemcitabine plus cisplatin combination as second-line treatment in patients with metastatic breast cancer (MBC)

774 Background: Gemcitabine and Cisplatin are active drugs in the treatment of MBC; this combination proved its effectiveness in the second line setting after failure of previous therapy that included anthracyclines and/or taxanes. Objectives: The objective of the study is to evaluate the efficacy and safety of Gemcitabine plus cisplatin as second-line chemotherapy in patients with MBC who have failed previous first line treatment that included anthracyclines and/or taxanes. Methods: From June 2000 to February 2002, 25 pts received gemcitabine 1,000 mg/m2 30 min infusion on d1, 8- Cisplatin 75 mg/m2 d1-q21. Eligibility criteria: proven MBC not amenable to local therapy for curative intent; age 18–75 yrs; KPS >70%; prior chemotherapy with anthracyclines and/or Taxanes; previous hormonal therapy is allowed; adequate bone marrow, liver, and kidney functions; life expectancy exceeding 6 months; informed written consent. Patients' characteristics: Of the 25 patients enrolled in the study, 21 were evaluable; me...